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Background:We report the aetiology and outcome of bloodstream infections (BSI) occurring at two regional cystic ﬁbrosis (CF) centres (one adult,
one paediatric) between 1998 and 2006.
Methods: A retrospective analysis of all positive blood cultures during the study period was performed.
Results: During the study period 1691 blood culture sets were taken. Fifty-seven clinically signiﬁcant episodes of BSI in 48 people with CF (36
adult, 12 paediatric) were identiﬁed, along with 28 other episodes considered to be contamination or not clinically signiﬁcant. The most common
BSIs were caused by coagulase-negative staphylococci (13) Candida spp (10), and Stenotrophomonas maltophilia (8). The majority (82%) of sig-
niﬁcant BSIs were considered to originate from totally-implantable vascular access devices (TIVADs); only 9% were attributed to the lower respi-
ratory tract. The TIVAD was removed in two-thirds of cases of TIVAD-associated BSI. There were three deaths (60% of cases) attributable to BSI
originating from the lower respiratory tract but no deaths attributable to TIVAD-associated BSI.
Conclusion:Most signiﬁcant BSIs in patients with CF originate from TIVADs. Targeted antimicrobial therapy and appropriate early device remov-
al is associated with good clinical outcome. BSI originating from the lower respiratory tract is associated with poor clinical outcome.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Bloodstream; Infection; Outcomes1. Introduction
Bloodstream infection (BSI) was first identified in associa-
tion with cystic fibrosis (CF) over 30 years ago [1,2]. Since
then, a wide range of fungal and bacterial pathogens have
been reported. Whilst there are several case series reporting
BSI in association with totally implanted vascular-access de-
vices (TIVADs) there are no systematic studies of BSI from
all sources in people with CF. We report here the results of a
retrospective review of episodes of BSI in people attending ei-
ther the Leeds Paediatric CF unit or the Leeds Adult CF unit⁎ Corresponding author at: Department of Microbiology, Old Medical School,
Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK. Tel.: +44
113 392 2922; fax: +44 113 392 2696.
E-mail address: miles.denton@leedsth.nhs.uk (M. Denton).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.02.004between 1st January 1998 and 31st December 2006, together
with an assessment of the likely clinical significance and
outcomes.
2. Method
Blood cultures were normally collected from patients pre-
senting to either unit with signs of systemic sepsis or if they de-
veloped rigours at the time of accessing their TIVAD. They
were not taken routinely during exacerbations. All blood cul-
ture samples collected from either CF unit, either as in- or
out-patient attenders, were identified from the laboratory com-
puter system. A retrospective review of the medical records
was undertaken for all positive blood cultures, and assessments
of both the clinical significance and the likely source of the bac-
teraemia made. The factors considered included the clinicalby Elsevier B.V. All rights reserved.
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(e.g. from an intravascular catheter and/or peripheral) and
need for antibiotic treatment or removal of TIVADs. The total
number of clinic attendees and the number with TIVADs
were obtained from the CF unit clinical database.
3. Results
During the study period 1691 blood culture sets were col-
lected. The annual number collected ranged from 129 to 290
sets (median 174 sets). The majority of sets (1341—79%)
were collected from peripheral venous stabs, 270 (16%) collect-
ed from TIVADs and the remaining 80 (5%) from a variety of
non-totally implanted vascular access devices. In total, 57 epi-
sodes of significant BSI were identified in 48 people (36 adults,
12 children) with CF. Forty two patients had one episode, three
had two episodes and three had three episodes. For those pa-
tients with more than one episode the causative organism was
different on each occasion. Causative organisms and clinical
outcomes are outlined in Table 1. Twenty eight other episodes
were deemed to be either contaminants or transient events not
requiring treatment.
The majority of BSIs were considered to have originated
from a TIVAD (47 episodes—82%). Of the remainder, five ep-
isodes (9%) were judged to have originated from the lower re-
spiratory tract, while the other five (9%) could not be attributed
to either. Although only five BSIs occurred in post-transplant
patients, two of these originated from the lower respiratory
tract. There was a 60% mortality associated with BSI from
the lower respiratory tract (one Burkholderia multivorans, oneTable 1
Causative organisms of significant BSI and their clinical outcome.
Organism No. of cases
Coagulase negative Staphylococci (CNS) 13
CNS+Candida albicans 2
Candida spp (C. albicans 2; C. parapsilosis 3;
C. tropicalis 1; one unidentified species)
7
Stenotrophomonas maltophilia 8
Staphylococcus aureus
(3 MSSA; 1 MRSA)
4
Corynebacterium species 3
Acinetobacter spp 3
Pseudomonas aeruginosa 2
Rhizobium radiobacter 2
Burkholderia multivorans 1
B. multivorans+P. aeruginosa 1
Burkholderia cenocepacia IIIA 1
Streptococcus pneumoniae 1
Ochrobacterium anthropi 1
Prevotella oralis 1
Enterobacter cloacae 1
Streptococcus mitis 1
Mixed C. albicans+E. cloacae+Enterococcus spp 1
Unidentified Pseudomonas spp 1
Enterococcus spp 3
Total 57 (48 patients)
a TIVAD: totally implantable vascular access device; LRTI, lower respiratory tracPseudomonas aeruginosa, and one mixed B. multivorans and
P. aeruginosa), compared with no attributable mortality (1
non-attributable death only) for TIVAD-associated BSI. None
of the BSIs were associated with clinical signs of endocarditis.
Of the 118 positive blood culture sets obtained in association
with the 57 BSIs, 68 were peripheral venous stabs, 37 were col-
lected from TIVADs and 13 from other intravascular devices.
Thus the positivity rates of blood cultures collected from
TIVADs (37/270—14%) and other intravascular devices (13/
80—16%) were higher than that of peripheral venous stabs
(68/1341—5%).
During the study period the number of people attending the
Adult CF Unit increased from 241 in 1998 to 335 in 2006,
although the proportion with TIVADs remained largely
unchanged (45%). Conversely the number of people attending
the Paediatric CF Unit remained unchanged (approximately
150) but the proportion with TIVADs increased from 20% to
40% over the same period. Despite the increase in the total
number of TIVADs there was no corresponding year-on-year
increase in either the total number of blood culture sets taken
or the number of TIVAD-associated BSIs over the study period
(data not shown).
4. Discussion
The use of TIVADs in CF has been described since the 1980s
[3,4]. Since then, there have been several case series reporting
their use and associated infection rates [5–7]. As in other reports,
we found the most common causative organisms of TIVAD-
associated BSI to be coagulase-negative staphylococci (13Presumed source(s) a Clinical outcome(s)
All TIVAD All survived
TIVAD Survived.
All TIVAD All survived
All TIVAD All survived
All TIVAD All survived
All TIVAD All survived
All TIVAD All survived
One TIVAD, one LRTI One survived (TIVAD source),
one died (LRT source)
Both TIVAD Both survived
LRTI Died
LRTI Died
LRTI Survived
LRTI Survived
TIVAD Died (but not attributed to BSI)
Unknown Survived
Unknown Survived
Unknown Survived
TIVAD Survived
TIVAD Survived
One TIVAD, two unknown Survived
47 TIVAD, 5 LRTI, 5 Unknown 44 survived, 4 died (one death
non-attributable to BSI)
t infection.
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cant number of multi-resistant Gram negative bacilli causing
TIVAD-associated BSI, most notably Stenotrophomonas malto-
philia (8 cases), Acinetobacter species (3 cases), and Rhizobium
(Agrobacterium) radiobacter (2 cases).
Outcome for patients with TIVAD-associated BSI was good
with no attributed deaths (one patient died for non-attributable
reasons (end-stage renal failure) within 7 days of an Ochrobac-
terium anthropi BSI). TIVAD-associated BSI triggered removal
in two-thirds of cases. All TIVAD-associated BSIs with Candida
species and S. maltophilia triggered early TIVAD removal as
recommended by other reports [8–10]. Attempts to salvage
TIVADs associated with BSIs caused by Gram positive bacteria
were madewhere clinically appropriate. Half of TIVADs infected
with coagulase negative staphylococci were salvaged by antibiot-
ic therapy alone, without the need for removal.
Conversely outcome of BSI originating from the lower re-
spiratory tract was poor, with three (60%) of five cases result-
ing in attributable death. These BSIs were a single case of
B.multivorans immediately post-liver transplantation, one case
of mixed B. multivorans and P. aeruginosa presenting as ‘cepa-
cia syndrome’ [11], and one case of P. aeruginosa in associa-
tion with end-stage CF. The one case of ‘cepacia syndrome’
caused by Burkholderia cenocepacia IIIA in this case series
survived.
Only five patients were post-transplantation when they had a
BSI. However, two of the five BSIs originating from the lower
respiratory tract occurred in this group, suggesting that immu-
nosuppression increases the risk of this event.
Blood cultures collected from TIVADs and other intravascu-
lar devices were more likely to be positive than peripheral ve-
nous stabs, highlighting the importance of collecting samples
from these sites when attempting to diagnose BSIs in people
with CF. It is also important to take simultaneous samples
from both TIVADs (or other intravascular devices) and periph-
eral venous stabs in order to calculate the differential time to
positivity [12]. This helps identify whether the source is more
likely to be the TIVAD and informs clinical decision-making
around TIVAD removal and antimicrobial therapy.
In this case series of BSIs in CF the majority were TIVAD-
associated. With targeted antibiotic therapy and, where appro-
priate, early line removal, clinical outcomes are very good.
Non-TIVAD-associated BSIs are far less common in CF, ac-
counting for only 18% of cases. However, BSIs originating
from the lower respiratory tract in people with CF are a poorprognostic indicator and are associated with high mortality.
Blood cultures are therefore an important investigation in peo-
ple with CF presenting with signs of systemic sepsis as the find-
ings may be of significant prognostic value.Acknowledgements
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